In study B7461001, of 295 patients with ALK-positive metastatic NSCLC who received lorlatinib 100 mg orally once daily, 0.7% occurred myocardial infarction which led to permanently discontinued lorlatinib treatment (Fala, 2019). This evidence concerns the gene ALK and non-small cell lung carcinoma.